AU688290B2 - A pharmaceutical formulation - Google Patents

A pharmaceutical formulation

Info

Publication number
AU688290B2
AU688290B2 AU55836/94A AU5583694A AU688290B2 AU 688290 B2 AU688290 B2 AU 688290B2 AU 55836/94 A AU55836/94 A AU 55836/94A AU 5583694 A AU5583694 A AU 5583694A AU 688290 B2 AU688290 B2 AU 688290B2
Authority
AU
Australia
Prior art keywords
dopa
active agent
formulation according
carrier
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU55836/94A
Other languages
English (en)
Other versions
AU5583694A (en
Inventor
Sten-Magnus Aquilonius
Christer Nystrom
Lennart Paalzow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie BV
Original Assignee
Neopharma Production AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharma Production AB filed Critical Neopharma Production AB
Publication of AU5583694A publication Critical patent/AU5583694A/en
Assigned to NEOPHARMA PRODUCTION AB reassignment NEOPHARMA PRODUCTION AB Alteration of Name(s) of Applicant(s) under S113 Assignors: AQUILONIUS, STEN-MAGNUS, NYSTROM, CHRISTER, PAALZOW, LENNART
Application granted granted Critical
Publication of AU688290B2 publication Critical patent/AU688290B2/en
Assigned to SOLVAY PHARMACEUTICALS B.V. reassignment SOLVAY PHARMACEUTICALS B.V. Alteration of Name(s) in Register under S187 Assignors: NEOPHARMA PRODUCTION AB
Anticipated expiration legal-status Critical
Assigned to ABBVIE B.V. reassignment ABBVIE B.V. Alteration of Name(s) in Register under S187 Assignors: SOLVAY PHARMACEUTICALS B.V.
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU55836/94A 1992-11-30 1993-11-29 A pharmaceutical formulation Expired AU688290B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9203594A SE9203594D0 (sv) 1992-11-30 1992-11-30 Laekemedel i dispersa system
SE9203594 1992-11-30
PCT/SE1993/001029 WO1994012153A1 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation

Publications (2)

Publication Number Publication Date
AU5583694A AU5583694A (en) 1994-06-22
AU688290B2 true AU688290B2 (en) 1998-03-12

Family

ID=20387973

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55836/94A Expired AU688290B2 (en) 1992-11-30 1993-11-29 A pharmaceutical formulation

Country Status (15)

Country Link
US (1) US5635213A (OSRAM)
EP (1) EP0670713B3 (OSRAM)
JP (1) JP3661703B2 (OSRAM)
AT (1) ATE184191T3 (OSRAM)
AU (1) AU688290B2 (OSRAM)
CA (1) CA2150464C (OSRAM)
DE (2) DE122005000021I1 (OSRAM)
DK (1) DK0670713T3 (OSRAM)
ES (1) ES2137350T7 (OSRAM)
FR (1) FR04C0024I2 (OSRAM)
GR (1) GR3031988T3 (OSRAM)
NL (1) NL300169I1 (OSRAM)
NZ (1) NZ258276A (OSRAM)
SE (1) SE9203594D0 (OSRAM)
WO (1) WO1994012153A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
JP4653893B2 (ja) * 2000-01-27 2011-03-16 純一 須藤 二層型経皮吸収製剤
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050119249A1 (en) * 2003-12-02 2005-06-02 Erik Buntinx Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) * 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005053796A1 (en) * 2003-12-02 2005-06-16 B & B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
RU2484815C2 (ru) * 2006-05-31 2013-06-20 Зольвай Фармасьютиклз Гмбх Продолжительное 24-часовое введение в кишечник леводопа/карбидопа
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
CA2691531C (en) 2007-06-22 2016-11-01 Board Of Regents,The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010056657A2 (en) 2008-11-16 2010-05-20 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2653179B1 (en) 2012-04-17 2019-07-10 Micrel Medical Devices S.A. System for calculating and administering a drug to a patient with Parkinson's disease
ES2973289T3 (es) 2014-09-04 2024-06-19 Lobsor Pharmaceuticals Ab Composiciones farmacéuticas en gel que comprenden levodopa, carbidopa y entacapona
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX393568B (es) 2014-10-21 2025-03-24 Abbvie Inc Profarmacos de carbidopa y l-dopa y metodos de uso
MA41377A (fr) * 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
BR112019001082A2 (pt) * 2016-07-20 2019-04-30 Abbvie Inc. gel intestinal de levodopa e carbidopa e métodos de uso
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US11844860B2 (en) 2018-03-02 2023-12-19 Chiesi Farmaceutici S.P.A. Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
AU2019237857B2 (en) 2018-03-23 2024-11-21 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
UY38473A (es) 2018-11-15 2020-06-30 Abbvie Inc Formulaciones farmacéuticas para una administración subcutánea

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1567890A (en) * 1977-03-30 1980-05-21 Boehringer Mannheim Gmbh Instillation composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4356824A (en) * 1980-07-30 1982-11-02 Vazquez Richard M Multiple lumen gastrostomy tube
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
GB8720600D0 (en) * 1987-09-02 1987-10-07 Saad Al Damluji Pharmaceutical compositions
US4863962A (en) * 1988-03-02 1989-09-05 Fidia-Georgetown Institute For The Neurosciences D-DOPA, pharmaceutically acceptable salts thereof, and methods of treating Parkinson's disease
US5326572A (en) * 1989-03-23 1994-07-05 Fmc Corporation Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1567890A (en) * 1977-03-30 1980-05-21 Boehringer Mannheim Gmbh Instillation composition

Also Published As

Publication number Publication date
FR04C0024I2 (OSRAM) 2010-12-31
ATE184191T3 (de) 1999-09-15
JPH08504764A (ja) 1996-05-21
DK0670713T3 (da) 2000-03-20
EP0670713A1 (en) 1995-09-13
DE69326350T3 (de) 2018-01-11
SE9203594D0 (sv) 1992-11-30
CA2150464C (en) 2002-02-05
EP0670713B1 (en) 1999-09-08
FR04C0024I1 (OSRAM) 2004-03-12
DE69326350D1 (de) 1999-10-14
GR3031988T3 (en) 2000-03-31
DE69326350T2 (de) 2000-01-27
WO1994012153A1 (en) 1994-06-09
NL300169I1 (nl) 2005-03-01
NZ258276A (en) 1996-09-25
US5635213A (en) 1997-06-03
ES2137350T3 (es) 1999-12-16
DE122005000021I1 (de) 2006-02-23
CA2150464A1 (en) 1994-06-09
ES2137350T7 (es) 2017-11-13
JP3661703B2 (ja) 2005-06-22
AU5583694A (en) 1994-06-22
EP0670713B3 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
US5635213A (en) Pharmaceutical formulation
CA1156552A (en) Aging resistant aluminum ibuprofen pharmaceutical suspensions
CN100415234C (zh) 生物利用度提高的抗真菌组合物
JPS61500223A (ja) 医薬組成物
JP3038456B2 (ja) ジデオキシプリンヌクレオシドの改良された経口投与処方物
LV10918B (en) Method of use of azithromycin
JP3480939B2 (ja) アモキシシリンおよびクラブラン酸含有の組成物
GB2100985A (en) Compositions containing buprenorphine
US20020028794A1 (en) Megestrol acetate suspension
JP2001521495A (ja) 飲料用液体の単一製剤形のミネラルおよびビタミンの治療用組合わせ
KR890000907B1 (ko) 안정한 현탁액 제조용 고체 약물 제형의 제조방법
US11844860B2 (en) Pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa
CA1288354C (en) Guar flour
JP2511577B2 (ja) アルギン酸プロピレングリコ―ルエステルからなる徐放性製剤
US2841526A (en) Fatty acid-resin adsorption product
CA2356177A1 (en) Aqueous pharmaceutical compositions
CN100542539C (zh) 用于紧急糖皮质激素治疗的药物组合物
EP0248740A2 (en) A composition of aluminium hydroxide gel
WO2021050320A1 (en) Pharmaceutical compositions comprising heparinoids and methods for preparing thereof
JPS5824514A (ja) 消化性潰瘍治療剤
JPH0458453B2 (OSRAM)
US4725625A (en) Pharmaceutical composition and method for treating cachexia in humans due to cancer
EP1075257A1 (en) Use of triclosan for the treatment of helicobacter pylori infections
JPH04288013A (ja) 懸濁シロップ剤
JPH05186331A (ja) 経口経管栄養剤